JM-221 is a novel platinum(IV) dicarboxylate complex exhibiting enhanced cytotoxicity in human ovarian carcinoma cell line when compared to Cisplatin. Comparison with platinum accumulation from Cisplatin suggests that the increased cytotoxicity of JM-221 may be related_x000D_
to increased accumulation within the cell. JM-221 is more lipophilic than Cisplatin, which may account for improved uptake in Cisplatin resistant cells.
